Cypherpunk Technologies Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, executive compensation, and auditor ratification, with all proposals receiving substantial support. Voting procedures and quorum were confirmed, and preliminary results will be filed with the SEC.
Fiscal Year 2025
-
A virtual special meeting addressed proposals to increase authorized shares, conduct a reverse split, adopt a new equity plan, and approve a private placement. All proposals were voted on with a quorum present, and preliminary results were announced.
-
Sirexatamab shows promising efficacy and tolerability in metastatic colorectal cancer, especially in patients with high plasma DKK1 or who are VEGF-naive, with improved response rates and progression-free survival over standard care. Ongoing data suggest durable benefit and support further phase 3 evaluation.
-
Sirexatamab plus standard therapy showed a significant ORR improvement in second-line colorectal cancer, especially in DKK1-high, VEGF-naive, and EGFR-experienced subgroups. DKK1 levels strongly correlated with response, supporting phase III planning in CRC, while gastric cancer development will not proceed to phase III.
-
Leap’s lead antibody, now named sirexatamab, is advancing in two pivotal trials for gastric and colorectal cancer, with promising early results, especially in bevacizumab-naive and left-sided colorectal cancer patients. The FL-501 program for cancer cachexia is also progressing, with preclinical data expected soon.
Fiscal Year 2024
-
Lead asset DKN-01 is advancing in phase 2 trials for gastric and colorectal cancers, with key data readouts expected late 2024 to mid-2025. Subgroup analyses and strategic partnerships are central to future phase 3 plans, while pipeline expansion includes a novel GDF15 antibody.